The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
KEYMAKER-U06 substudy 06A trial in progress: A phase 1/2 study of investigational agents with pembrolizumab (pembro) plus chemotherapy (chemo) or lenvatinib in PD-1/L1 treatment-naïve advanced esophageal cancer.
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Toshihiko Doi
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Ono Pharmaceutical; Rakuten Medical Japan; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie; Amgen; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Janssen; Kaken Pharmaceutical; Kyowa Hakko Kirin; KYOWA KIRIN; MSD; Otsuka; Otsuka; PRA Health Sciences; Rakuten Medical; SHIONOGI; Sumitomo Dainippon; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); IQvia (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); PRA Health Sciences (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst)
 
Jaafar Bennouna
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Roche
Research Funding - AstraZeneca; Merck
Travel, Accommodations, Expenses - AstraZeneca; Roche
 
Jong-Mu Sun
No Relationships to Disclose
 
Thomas Jemielita
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Kanu Sharan
Employment - Medtronic (I); Merck
Leadership - Medtronic (I)
Stock and Other Ownership Interests - Medtronic (I); Merck
 
Pooja Bhagia
Employment - Merck
Stock and Other Ownership Interests - Merck
Research Funding - Merck
 
Antoine Adenis
Consulting or Advisory Role - Arcus Biosciences; Astellas Pharma; Bayer Health; Bristol-Myers Squibb; Merck; Merck Serono
Speakers' Bureau - Bristol-Myers Squibb; MSD Oncology; Novartis
Research Funding - Arcus Ventures (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Roche (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Pierre Fabre; SERVIER